Pre-Hospital Use of Plasma for Traumatic Hemorrhage

Shock, Hemorrhagic Clinical Trial

— PUPTH  

Official title:

Pre-Hospital Use of Plasma for Traumatic Hemorrhage

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02303964
• Other study ID #: HM14813
• Secondary ID: IND #15910W81XWH
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• First received: October 6, 2014
• Last updated: February 19, 2016
• Start date: November 2014
• Est. completion date: January 2016

Study information

• Verified date: February 2016
• Source: Virginia Commonwealth University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Type A Thawed Plasma (TP) will be compared in polytrauma patients who receive only Normal Saline (NS) (standard of care) before arrival at the hospital.

The purpose of this study is to determine if prehospital administration of thawed plasma can reduce mortality of patients who have lost a large amount of blood due to their injuries, compared to those receiving standard of care.

Description:

INVESTIGATIONAL PLAN This will be an open-label, non-blinded, randomized clinical trial to investigate mortality (30 days) and morbidity of Type A thawed Plasma (TP) versus NS infusion at earliest contact, administered by Emergency Medical Service (EMS) supervisors to subjects who have sustained severe Polytrauma / Major hemorrhage (PTr / MH). The total study is expected to last 2 years with 210 patients enrolled.

The two EMS agencies involved in the study will each have one EMS supervisor quick-response vehicle (QRV) equipped with an approved, validated refrigeration unit for TP transport. EMS personnel trained in plasma administration and recognition of reactions may administer up to 2 units of TP to subjects approved for study enrollment. Blood samples for coagulation and lipid testing will be drawn prior to TP administration by EMS personnel,and repeated by hospital personnel at 30 minutes, 8 hours, and 24 hours post-injury.

This study is approved for "Exception from Informed Consent" (EFIC). Once the patient has reached VCUMC and has been entered into the VCUMC health care system, the treating team will advise the Study Coordinator (SC) whether or not a subject is able to consent. As the plasma administration will occur in the field prior to arrival to VCUMC, the SC will make every effort possible to obtain consent from the subject or legally authorized representative (LAR) for continued study participation before the next intervention (8 hour blood specimen collection). The attempts to contact the LAR will be documented in detail. If a subject lacks the ability to provide his/her own consent by the end of day 30, the consent signed by the LAR will be the consent document in force at the subject's completion of the study and no further consent will be sought.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Blunt or penetrating trauma,

• Blood Pressure (BP) systolic <70 mmHg or BP 70-90 mmHg with Heart Rate (HR) > 108 Beats Per Minute (BPM),

• Ongoing hemorrhage with unstable vital signs

Exclusion Criteria:

• Wearing opt-out wrist band,

• Wearing medical alert jewelry / bracelet, etc. indicating Jehovah Witness or similar with objections to blood transfusions,

• Refusal to participate (by subject or LAR),

• Communication barrier at the time of eliciting refusal (non-English speaking or non-Spanish speaking),

• Not expected to survive transport to Virginia Commonwealth University Medical Center (VCUMC),

• Documented Do Not Resuscitate (DNR) order found,

• Cardiac arrest or Cardio-Pulmonary Resuscitation (CPR) prior to randomization

• Penetrating head trauma,

• Known / obvious pregnancy,

• Prisoner,

• Burns > 20% of body surface

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hemorrhage
• Shock, Hemorrhagic

Intervention

Biological:
• Plasma
Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study

Drug:
• Normal saline
Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study

Locations

Country	Name	City	State
United States	Virginia Commonwealth University	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Virginia Commonwealth University	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	all cause mortality	30 day	Yes
Secondary	Coagulation function (thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry)	thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry	24 hours	No
Secondary	Vital signs (blood pressure, pulse, temperature)	blood pressure, pulse, temperature	24 hours	No
Secondary	Blood product utilization (number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses)	number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses	30 days	No
Secondary	Lipidomic profiles (arachidonic acid, eicosinoid expression, prostacyclin expression)	arachidonic acid, eicosinoid expression, prostacyclin expression	24 hours	No
Secondary	Blood biochemistry (pH, bicarbonate, lactate)	pH, bicarbonate, lactate	24 hours	No
Secondary	Hematology (Hemoglobin, hematocrit)	Hemoglobin, hematocrit	24 hours	No
Secondary	Hospital outcomes (number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections)	number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections	30 days	No